Ebook: Novel Approaches to the Treatment of Alzheimer’s Disease

Section I. Drugs that Act at Cholinergic Receptors.- A Functionalized Congener Approach to Muscarinic Ligands.- AF102B: A Novel M1 Agonist as a Rational Treatment Strategy in Alzheimer’s Disease.- Muscarinic Receptors, Phosphoinositide Hydrolysis and Neuronal Plasticity in the Hippocampus.- Effects of Cholinergic Drugs on Extracellular Levels of Acetylcholine and Choline in Rat Cortex, Hippocampus and Striatum Studied byu Brain Dialysis.- Delayed Matching-to-Sample in Monkeys as a Model for Learning and Memory Deficits: Role of Brain Nicotinic Receptors.- Muscarinic and Nicotinic Receptors in Alzheimer’s Disease: Rationale for Cholinergic Drug Treatment.- Section II. CNS-Active Neurotrophic Factors.- Potential Pharmacological Use of Neurotrophic Factors in the Treatment of Neurodegenerative Diseases.- The Use of Reaggregating Cell Cultures and Immortalized Central Nervous System Cells to Study Cholinergic Trophic Mechanisms.- Approaches to Gene Therapy in the CNS: Intracerebral Grafting of Fibroblasts Genetically Modified to Secrete Nerve Growth Factor.- Exogenous Nerve Growth Factor Stimulates Choline Acetyltransferase Activity in Basal Forebrain of Axotomized and Aged Rats.- Neuronotrophic Factors, Gangliosides and Their Interaction: Implications in the Regulation of Nervous System Plasticity.- Suppression of Active Neuronal Death by Immune Interferon.- Basic Fibroblast Growth Factor, an Example of a Multifunctional Trophic Factor with Neurotrophic Activity.- Growth Factor and Lymphokine Effects on Brain Cholinergic Systems.- Metabolic Support of Neural Plasticity: Implications for the Treatment of Alzheimers Disease.- Section III. Additional Novel Treatment Strategies: Improved Brain Delivery, Hormones, and Immunology.- Brain-Enhanced Delivery of Anti-Dementia Drugs.- Development of a Pyrrolidinone Derivative (Cyclic GABA)for Modulating Brain Glutamate Transmission.- A Brain-Enhanced Chemical Delivery System for Gonadal Steroids: Implications for Neurodegenerative Diseases.- Immunologic Approach to Therapy in Alzheimer’s Disease.- The Influence of ACTH 4–9 Analog upon Avoidance Learning in Normal and Brain Damaged Rats.- Section IV. Models for Drug-Development: Cholinergic Hypofunction.- Transneuronal Neurochemical and Neuropathological Changes Induced by Nucleus Basalis Lesions: A Possible Degenerative Mechanism in Alzheimer’s Disease.- Presynaptic Markers of Cholinergic Function in Cortex Following Ibotenic Acid Lesion of the Basal Forebrain.- Cholinergic-Neuropeptide Y Interactions in the Rat Cerebralcortex: Towards a Model for the Trans-synapticEffects of Cholinergic Transmission.- The Effects of Nucleus Basalis Lesions in the Rat on One Way Passive and Active Avoidance, Two Way Avoidance and Lashly III Maze Learning: An Animal Model for SDAT.- Section V. Models for Drug Development: Other Neurochemical and Behavioral Changes.- NMDA Receptors, Aging and Alzheimer’s Disease.- An Excitotoxic Model of Alzheimer’s Disease: NMDA Lesions and Initial Neural Grafting Results.- Excitotoxin Mediated Neuronal Loss and the Regulation of Excitatory Amino Acid Release in the Aging Brain.- EEG Power Spectra and Brain Function.- Postmortem Stability of RNA Metabolism in Human Brain: Studies of the Nondemented Conrol and Alzheimer’s Disease Cases.- A Model System Demonstrating Parallels in Animal and Human Aging: Extension to Alzheimer’s Disease.- Computer-Simulated Everyday Memory Testing for Clinical Trials in Memory Disorders of Aging.